109results about How to "Prevent and treat disease" patented technology

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same.

Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.

To provide a diagnostic drug which binds specifically to an amyloid aggregate and/or an amyloid deposit, to thereby realize imaging and quantification of a disease caused by amyloid aggregation and/or deposition.

The invention provides a compound represented by formula (1):

(wherein X¹ represents an optionally substituted bicyclic heterocyclic group;

• • X² represents a hydrogen atom, a halogen atom, or a chelate-forming group;
  • ring A represents a benzene ring or a pyridine ring; and
  • ring B represents an optionally substituted 5-membered aromatic heterocyclic group which is bonded to the benzene ring or the pyridine ring via a carbon atom of ring B), a salt thereof, a solvate of any of these, or a transition metal coordination compound of any of these, and a diagnostic, preventive, or therapeutic drug containing the same.

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

It is intended to provide preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis characterized by containing a specific compound having a CCR (CC chemokine receptor) antagonism.

Methods and materials to modulate the immune response to treat or prevent a disease, including methods of making T helper-antigen presenting cells and methods of using these cells. The invention also relates to methods of making exosome-absorbed dendritic cells and the uses of these cells to modulate the immune response to treat or prevent a disease.

Disclosed herein is a method for treating diseases associated with beta amyloid accumulation, including administering to a patient a therapeutically effective amount of morpholine or piperazine based compounds including a sulfuric or carboxylic acid structure represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof:

The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) and a signal transduction modifying protein, selected from one of the following: (i) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), but lacks a kinase domain; (ii) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a phosphatase domain; (iii) a fusion protein which comprises (a) an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) or from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM); and (ii) a heterologous domain.

The present invention relates to a composition comprising a Moutan root bark extract as an active ingredient, and particularly to a composition for the prevention and treatment of athlete's foot, osmidrosis, or acne; a composition for oral cleansing; a bactericidal/disinfectant composition; a composition for eliminating dandruff-causing pathogens and controlling odor, and a functional kitchen detergent composition. The compositions comprising the Moutan root bark extract as an active ingredient of the present invention have superior bactericidal effects against bacteria including athlete's foot-causing pathogens, skin eczema-causing pathogens and skin flora, and fungi, and they can be easily and simply applied to medicines, cosmetics, or cleansing agents.

The present invention provides a compound represented by the formula:

wherein R¹ is a C_1-4 alkyl; R² is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a hydroxy group, (3′) a C_1-4 alkyl and (4′) a C_1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a C_1-4 alkoxy-C_1-4 alkyl, (3′) a mono-C_1-4 alkyl-carbamoyl-C_1-4 alkyl, (4′) a C_1-4 alkoxy and (5′) a mono-C_1-4 alkylcarbamoyl-C_1-4 alkoxy, or the like; R³ is a C_1-4 alkyl; R⁴ is a C_1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.

The present invention provides a safe pet food material having an anti-stress action and effect of increasing palatability. Livestock meat or fish meat is treated with a protease such as papain to obtain a pet food material with excellent thermal stability having peptides consisting of 2-10 amino acid residues as a principal active ingredient. A pet food exhibiting an anti-stress action and having high palatability is obtained by blending this material.

The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method.

The present invention provides a new patentable class of purine analog compounds, as well as compositions and methods of using them, for example, to prevent or treat various diseases and disorders in human and non-human animals.

The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

The present invention relates to a novel human-derived cell permeable peptide-bioactive peptide conjugate and the use thereof.

According to the present invention, cationic cell permeable peptides derived from human bone morphogenetic protein-4 have no toxicity and immuno-genicity and thus exhibit high stability as compared to viral peptide delivery vehicles, and can transport cell impermeable material into cells and into an organism without any damage to cell or material, thereby significantly increasing target gene expression. In addition, the peptide may be applied to clinical use without having to undergo a large number of processes and mass-produced, such that the present invention may be useful in the development of a drug delivery system and treatment technologies using said peptide.